What's in JW Pharmaceutical's pipeline?

JW Pharmaceutical has 32 drugs in our index: 5 marketed, 0 filed, 14 in Phase 3, 2 in Phase 2, 11 in Phase 1.

Which companies overlap with JW Pharmaceutical's portfolio?

Top competitors by shared drug class: Ain Shams University, Sanofi, Chong Kun Dang Pharmaceutical, AstraZeneca, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jw-pharmaceutical.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

JW Pharmaceutical — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JW Pharmaceutical pipeline: 5 marketed, 0 filed, 14 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 14 Phase 3 2 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
recomon (Epoetin Beta)	recomon (Epoetin Beta)	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)	Hematology
Anagliptin BID Treatment	Anagliptin BID Treatment	marketed	DPP-4 inhibitor	Dipeptidyl peptidase-4 (DPP-4)	Diabetes
venoferrum(iron sucrose)	venoferrum(iron sucrose)	marketed	Iron replacement agent		Hematology
Placebo (for Pitavastatin)	Placebo (for Pitavastatin)	marketed
VA	VA	marketed	Antiviral		Infectious Diseases
JTZ-951	JTZ-951	phase 3	Apelin receptor antagonist	APJ (apelin receptor)	Cardiovascular
JW0108 + C2407	JW0108 + C2407	phase 3			Oncology
JW0201	JW0201	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Livalo, Ezetrol	Livalo, Ezetrol	phase 3	Statin (pitavastatin) and cholesterol absorption inhibitor (ezetimibe)	HMG-CoA reductase (pitavastatin); NPC1L1 transporter (ezetimibe)	Cardiovascular
LivaloV	LivaloV	phase 3	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
LivaloVA	LivaloVA	phase 3	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
Treatment Period(Placebo)	Treatment Period(Placebo)	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Cardiovascular · 4
Diabetes · 4
Oncology · 3
Hematology · 2
Infectious Diseases · 1
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 5 shared drug classes
Sanofi · 3 shared drug classes
Chong Kun Dang Pharmaceutical · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Pfizer · 3 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 3 shared drug classes
Takeda · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for JW Pharmaceutical:

Cite this brief

Drug Landscape (2026). JW Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jw-pharmaceutical. Accessed 2026-05-16.